Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics

Core Insights - Wall Street analysts expect Insulet (PODD) to report quarterly earnings of $1.05 per share, reflecting a year-over-year decline of 25$581.65 million, which represents a 14.1% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [1] Revenue Estimates - Analysts forecast 'Revenue- Total Omnipod' to reach $575.12 million, indicating a year-over-year change of +14.8$6.07 million, reflecting a decline of 31% from the previous year [4] - 'Revenue- International Omnipod' is expected to be $140.18 million, showing a year-over-year increase of +31.8$434.94 million, indicating a change of +10.2% from the prior-year quarter [5] Stock Performance - Over the past month, Insulet shares have recorded returns of +3.4%, compared to the Zacks S&P 500 composite's +4.9% change [5] - Insulet holds a Zacks Rank 3 (Hold), suggesting that its performance is expected to align with the overall market in the upcoming period [5]